New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
Trial reflecting real-world practice showed a reduction in the rate of asthma attacks compared to the most commonly used reliever therapy
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of?Symbicort Turbuhaler?(budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.1
These results are published in the?New England Journal of Medicine?and are being presented at the American Thoracic Society 2019 International Conference.1
The trial compared?Symbicort Turbuhaler?with two commonly used treatment regimens in mild asthma. In real-world practice, patients typically use a short-acting beta2-agonist (SABA) reliever in response to symptoms or daily low-dose inhaled corticosteroid (ICS) maintenance therapy with a SABA reliever. In this trial, patients with mild asthma were randomised to receive either albuterol (a SABA reliever) taken as-needed, or budesonide (an ICS maintenance treatment) plus albuterol as-needed, or?Symbicort Turbuhaler?used as an anti-inflammatory reliever therapy taken as-needed.1
Symbicort Turbuhaler?demonstrated a 51% reduction in the rate of annual asthma exacerbations compared to albuterol. There was no difference in the exacerbation rate between?Symbicort Turbuhaler?and twice-daily maintenance budesonide plus albuterol, despite a 52% reduction in the mean steroid dose with?Symbicort Turbuhaler.1?These data support the findings of the SYGMA 1 and 2 trials published in May 2018.2,3
Alex de Giorgio-Miller, Therapy Area Vice President, Respiratory, Global Medical Affairs, said: ?There are an estimated 176 million asthma attacks globally each year and all asthma patients, regardless of their disease severity, are at risk of severe attacks. The Novel START trial demonstrates the effectiveness of?Symbicort?as an anti-inflammatory reliever to reduce the risk of asthma attacks in patients with mild disease, compared with the most commonly used asthma reliever. In a trial that reflects real-world practice, these data reinforce evidence from the SYGMA trials and build on the established clinical profile of?Symbicort?in moderate-to-severe disease.?
Professor Richard Beasley, Director of the Medical Research Institute of New Zealand said: ?Asthma attacks are a major burden in mild disease. SABA relievers do not address the underlying inflammation in asthma, and patients with mild disease who rely on SABA alone are at greater risk of asthma attacks than those taking an anti-inflammatory therapy. Novel START showed that?Symbicort?used as an anti-inflammatory reliever was superior to as-needed SABA for the prevention of asthma attacks in mild disease.?
Novel START was conducted by the Medical Research Institute of New Zealand and was funded by a research grant from AstraZeneca and core institutional funding from the Health Research Council of New Zealand.
Safety and tolerability data for?Symbicort Turbuhaler?as-needed were consistent with the known profile of the medicine. The most commonly reported adverse events in the Novel START trial were upper respiratory tract infection, nasopharyngitis and asthma.1
Symbicort Turbuhaler?is approved as a maintenance and reliever therapy in many countries for moderate-to-severe asthma, and as an?anti-inflammatory reliever as-needed in patients with mild asthma in Brazil and Russia. A regulatory?submission to expand the indication for?Symbicort Turbuhaler?as an?anti-inflammatory reliever in mild asthma has been accepted in Europe. In the US,?Symbicort?is approved for use in a pressurised metered-dose inhaler device, but not the?Turbuhaler?device.
About Novel START
Novel START (Novel?Symbicort Turbuhaler?Asthma Reliever Therapy) is Externally Sponsored Scientific Research (ESR). The primary objective of the trial was to assess the efficacy of?Symbicort Turbuhaler?given as an anti-inflammatory reliever as-needed in adults with mild asthma.
The 52-week pragmatic trial supports the findings of the double-blind, double-dummy SYGMA trials (also published in the?New England Journal of Medicine), but in an open-label treatment regimen reflecting real-world practice in 668 patients aged 18-75 years in Australia, Italy, New Zealand and the UK with a self-reported doctor-diagnosis of asthma. Patients were enrolled if they had used a SABA inhaler as sole asthma therapy in the previous 3 months and required use of SABA on =2 occasions in the previous 4 weeks (but on average =2 occasions per day in the previous 4 weeks). In the trial,?Symbicort Turbuhaler?as-needed (200/6 ?g; n=220) was compared to SABA treatment with albuterol (known as salbutamol in many countries) as-needed (100 ?g; n=223), and maintenance ICS therapy with budesonide twice-daily plus albuterol as-needed (200 ?g and 100 ?g, respectively; n=225). These comparators reflect two of the treatment options most commonly used in clinical practice for the management of mild asthma.
The results of the primary outcome measurements are:
- Symbicort Turbuhaler?demonstrated a 51% reduction in the rate of annual asthma exacerbations versus SABA treatment with albuterol as-needed (absolute rate 0.195 vs 0.400 per patient per year, respectively; relative rate 0.49 (95% CI 0.33 to 0.72), P<0.001).
- There was no difference in the exacerbation rate between?Symbicort Turbuhaler?as-needed and maintenance budesonide plus as-needed albuterol (absolute rate 0.195 and 0.175 per patient per year, respectively; relative rate 1.12 (95% CI 0.70 to 1.79), P=0.65). (The mean budesonide dose with?Symbicort Turbuhaler?as-needed and maintenance budesonide was 107 ?g/day and 222 ?g/day, respectively.)
CONTACTS
Media Relations |
||
Gonzalo Vi?a | +44 203 749 5916 | |
Rob Skelding | Oncology | +44 203 749 5821 |
Rebecca Einhorn | Oncology | +1 301 518 4122 |
Matt Kent | BioPharma | +44 203 749 5906 |
Jennifer Hursit | Other | +44 203?749 5762 |
Christina?Malmberg H?gerstrand | Sweden | +46 8?552 53 106 |
Michele Meixell | US | +1 302 885 2677 |
Investor Relations |
||
Thomas Kudsk Larsen | +44 203 749 5712 | |
Henry Wheeler | Oncology | +44 203 749 5797 |
Christer Gruvris | BioPharma (cardiovascular; metabolism) | +44 203 749 5711 |
Nick Stone | BioPharma (respiratory; renal) | +44 203 749 5716 |
Josie Afolabi | Other | +44 203 749 5631 |
Craig Marks | Finance; Fixed Income | +44 7881 615 764 |
Jennifer Kretzmann | Retail Investors; Corporate Access | +44 203 749 5824 |
US toll-free | +1 866 381 72 77 | |